Search - tctmd.com

Displaying 41 - 60 of 107

Sort: Relevancy | Date

News Conference News TCT 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

Caitlin E. Cox

October 01, 2019

News Daily News

FFRCT Feasible in the ED Setting for Acute Chest Pain Patients

Caitlin E. Cox

July 25, 2019

News Conference News EuroPCR 2019

Early Days With OCT-Derived FFR Technology, but New Data Suggest Promise

Caitlin E. Cox

June 06, 2019

News Conference News SCAI 2019

FFR Changes Treatment Plan in More Than One-Third of All-Comer Patients

Yael L. Maxwell

June 04, 2019

News Features

Top News in Imaging: 2018

Caitlin E. Cox

December 28, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Presentation ESC 2018

FUnctional Testing Underlying REvascularization The FUTURE trial

Presenter: Gilles Rioufol

August 26, 2018

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

Todd Neale

August 26, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

Caitlin E. Cox

June 01, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

Caitlin E. Cox

May 22, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

News Conference News ACC 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Caitlin E. Cox

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Routine Use of FFR, iFR Changes Treatment Plans, Even in Patients With Multivessel Disease

Todd Neale

February 21, 2018

News Daily News

iFR May Help Rule Out Significant Nonculprit Lesions After Primary PCI

Todd Neale

November 30, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Advertisement

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

FFRCT Feasible in the ED Setting for Acute Chest Pain Patients

Early Days With OCT-Derived FFR Technology, but New Data Suggest Promise

FFR Changes Treatment Plan in More Than One-Third of All-Comer Patients

Top News in Imaging: 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

FUnctional Testing Underlying REvascularization The FUTURE trial

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

TCTMD’s Top 10 Most Popular Stories for May 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

TCTMD’s Top 10 Most Popular Stories for April 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Routine Use of FFR, iFR Changes Treatment Plans, Even in Patients With Multivessel Disease

iFR May Help Rule Out Significant Nonculprit Lesions After Primary PCI

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content